
MRNA Stock Down 10%, Moderna Didn’t Produce Data Critical to Assessing COVID-19 Vaccine
As Stat News has reported, it is too early to assess the COVID-19 vaccine offered by Moderna. Most of what Moderna disclosed “were words, not data”, while the critical information has been withheld. MRNA stock is down.